SPHS News 3.27 Sophiris Bio Inc (SPHS)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 18, 2014 at 1:29 AM

Sophiris Bio Inc (SPHS) 3.27 $SPHS

Sophiris Bio to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Tue Mar 25, 3:05PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference. The presentation is scheduled for Tuesday, April 8th at 3:00 p.m. EDT at the Westin Grand Central Hotel in New York, New York.

Sophiris names Gerald T. Proehl to board
M2 - Fri Mar 21, 5:21AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) stated on Thursday that Gerald T. Proehl has been elected to its board of directors with effect from 19 March 2014.

Sophiris Adds Gerald T. Proehl to its Board of Directors
Business Wire - Thu Mar 20, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced the appointment of Gerald T. Proehl to its board of directors effective March 19, 2014.

Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights
Business Wire - Thu Mar 13, 3:15PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.

Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:02AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 2014 Leerink Global Healthcare Conference. The presentation is scheduled for Wednesday, February 12, 2014 at 11:05 a.m. EST at the Waldorf Astoria Hotel in New York, New York.

3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Stocks Under $10 Moving Higher
at The Street - Wed Nov 20, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
Business Wire - Tue Nov 12, 3:05PM CST
Sophiris Bio Inc. (Sophiris, NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and nine months ended September 30, 2013.

Sophiris Bio Applies for Voluntary Delisting from TSX
Business Wire - Tue Nov 05, 3:05PM CST
Sophiris Bio Inc. (NASDAQ:SPHS) (TSX: SHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has applied for voluntary delisting of its common shares from the Toronto Stock Exchange ("TSX"

. Sophiris' common shares are currently listed for trading on the NASDAQ Global Market and the TSX. After delisting from the TSX, the Company's shares will continue to trade on NASDAQ under the symbol "SPHS".

Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Business Wire - Mon Oct 28, 3:05PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (TSX: SHS) today announced that enrollment has begun and the first patients have been dosed in a Phase 3 trial of PRX302 (topsalysin) as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH or enlarged prostate). The Phase 3 international, multi-center study, called the PLUS-1 study, will enroll approximately 440 patients. The randomized, double-blind and vehicle-controlled study will assess the safety and efficacy of a single intraprostatic injection of PRX302 (0.6 ug/g prostate) for the treatment of BPH. The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks. Secondary endpoints include Qmax change from baseline (maximum urine flow) over 52 weeks.

Sophiris Bio to Present at the Stifel Healthcare Conference
PR Newswire - Thu Sep 05, 4:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has closed its previously announced initial U.S. public offering (the "Offering"

. The Company issued 13,000,000 common shares at a price of US$5.00 per share for aggregate gross proceeds of US$65 million.

Sophiris Bio shares slump in debut
AP - Fri Aug 16, 11:50AM CDT
NEW YORK (AP) — Shares of Sophiris Bio Inc. tumbled Friday after the drug developer slashed the price of its initial public offering while boosting the number of shares being sold.

IIROC Trade Resumption - SHS
CNW Group - Fri Aug 16, 8:51AM CDT
Trading resumes in:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

Coastal Financial Faces Lawsuit Amid Massive Stock Hit

Coastal Financial Corporation's (NASDAQ:CCB) recent nosedive is more distressing than a rollercoaster ride. After a 43.52% stock drop, investors are furious, to say the least. What tipped the scales? Coastal's financial revelations painted a bleak picture, but that’s just scratching the surface of a mess that has folks heading for legal battles. Behind the Numbers: The...

SUNON's Approach to AI-Driven Workspaces Debuted at ORGATEC

SUNON's Unique Spin on Future Workspaces The world of workplace solutions is buzzing with ideas on how to blend smart tech with soulful spaces. This year, SUNON is hitting ORGATEC 2026 in Cologne with a bold approach that stitches AI, nature, and circular design right into the fabric of office life. They’re not just setting up shop; they’re promising a peek into a...

Coastal Faces Legal Storm: Investors Eyeing the Clock

Coastal Financial in the Crosshairs The stakes are big, folks. Coastal Financial Corporation (NASDAQ: CCB) is caught in a storm, and it's not a gentle breeze. A securities class action has hit the table, and it's drawing in investors like seagulls to a beach picnic. What Lit the Match? The story kicks off with a plummet so dramatic it turned heads and wallets upside...

Decoding the Risks and Rewards of Older Homes

Cracking Open the Older Homes Enigma You've got these older homes—charm oozing out of every nook and cranny but potential pitfalls hidden beneath every surface. I'm talking about that irresistible lure of historic details that come with a side of risk. Now, before you jump in with both feet, you might want to pause and consider what Lee Malcom from Malcom & Malcom...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

Dar Global Eyes Dubai for Strategic Real Estate Moves

Tapping into Dubai's Real Estate Allure Every seasoned investor knows the real estate game ain't for the faint of heart, especially when you’re playing in a market as competitive as Dubai's. But here comes Dar Global Capital Partners (DGCP), throwing their hat into the ring with a fresh strategy centered around high-value real estate. Sure, they aren't new to the...